Three CSF samples of a 60-year-old male patient diagnosed with ALK-rearrangement-positive NSCLC and receiving 250 mg crizotinib twice daily after developing brain metastases were assayed for crizotinib at one-week intervals following whole brain radiotherapy (an additional sample was processed before conducting WBRT). Here, ALK is linked to non-small cell lung carcinoma.